[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 32 of about 32
1. Arai H, Rino Y, Nishii T, Yukawa N, Wada N, Oshiro H, Ishida T, Nakaigawa N, Masuda M: Well-differentiated extraskeletal osteosarcoma arising from the retroperitoneum that recurred as anaplastic spindle cell sarcoma. Case Rep Med; 2010;2010:327591
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Well-differentiated extraskeletal osteosarcoma arising from the retroperitoneum that recurred as anaplastic spindle cell sarcoma.
  • Extraskeletal osteosarcoma is an uncommon high-grade malignant soft tissue sarcoma.
  • Well-differentiated extraskeletal osteosarcoma is thought to have a better prognosis than classical extraskeletal osteosarcoma, but dedifferentiation after recurrence has also been reported.
  • We present a case of a primary retroperitoneal extraskeletal osteosarcoma in a 62-year-old Japanese woman.
  • The histopathological diagnosis was well-differentiated retroperitoneal extraskeletal osteosarcoma.
  • She was followed up by CT every 6 months without adjuvant radiotherapy and chemotherapy for 31 months until anaplastic high-grade spindle cell sarcoma recurred in the retroperitoneum.
  • Our case is the seventh reported description of well-differentiated extraskeletal sarcoma, and the first to arise in the retroperitoneum and recur as an entirely dedifferentiated spindle cell sarcoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Radiol. 1991 Feb;64(758):171-2 [1900726.001]
  • [Cites] Arch Pathol Lab Med. 1991 Sep;115(9):906-9 [1929787.001]
  • [Cites] Cancer. 1990 Jun 15;65(12):2762-70 [2160317.001]
  • [Cites] Skeletal Radiol. 1989;18(6):471-4 [2814558.001]
  • [Cites] Cancer. 1987 Sep 1;60(5):1132-42 [3475157.001]
  • [Cites] Cancer. 1971 May;27(5):1121-33 [5281245.001]
  • [Cites] Hum Pathol. 2005 Apr;36(4):439-43 [15892008.001]
  • [Cites] Cancer. 1995 Dec 1;76(11):2253-9 [8635029.001]
  • [Cites] Am J Surg Pathol. 1998 May;22(5):588-94 [9591729.001]
  • [Cites] J Clin Pathol. 2001 Jan;54(1):77-8 [11271796.001]
  • [Cites] Skeletal Radiol. 2003 Mar;32(3):165-9 [12605283.001]
  • [Cites] Ann Surg. 1953 Nov;138(5):795-800 [13092816.001]
  • [Cites] J Natl Cancer Inst. 1995 Sep 6;87(17):1331-3 [7658488.001]
  • (PMID = 20224645.001).
  • [ISSN] 1687-9635
  • [Journal-full-title] Case reports in medicine
  • [ISO-abbreviation] Case Rep Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2833305
  •  go-up   go-down


2. Nagano A, Ohno T, Nishimoto Y, Yamada K, Shimizu K: Extraskeletal osteosarcoma of the thigh: an autopsy case report. Sarcoma; 2009;2009:186565
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraskeletal osteosarcoma of the thigh: an autopsy case report.
  • We report a case of extraskeletal osteosarcoma (ESOS) and autopsy findings.
  • The lung tumors continued to develop despite multiagent chemotherapy and caused death within 8 months.
  • Therefore, we made a definite diagnosis of ESOS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1990 Jun 15;65(12):2762-70 [2160317.001]
  • [Cites] Cancer. 1987 Sep 1;60(5):1132-42 [3475157.001]
  • [Cites] Cancer. 1973 Jun;31(6):1359-63 [4350957.001]
  • [Cites] Cancer. 1971 May;27(5):1121-33 [5281245.001]
  • [Cites] Skeletal Radiol. 2003 Mar;32(3):165-9 [12605283.001]
  • [Cites] J Clin Oncol. 2002 Jan 15;20(2):521-7 [11786582.001]
  • [Cites] Ann Surg. 1941 Jan;113(1):95-112 [17857721.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 Aug;131(8):520-6 [15918046.001]
  • [Cites] Radiat Med. 2005 Mar;23(2):142-6 [15827535.001]
  • [Cites] N Engl J Med. 1999 Jul 29;341(5):342-52 [10423470.001]
  • [Cites] Anticancer Res. 1998 Jan-Feb;18(1B):657-66 [9584049.001]
  • [Cites] Cancer. 1995 Dec 1;76(11):2253-9 [8635029.001]
  • [Cites] Radiographics. 1993 Jul;13(4):853-84 [8356273.001]
  • [Cites] Skeletal Radiol. 1989;18(6):471-4 [2814558.001]
  • [Cites] Cancer. 1983 Feb 15;51(4):727-34 [6571801.001]
  • (PMID = 19753130.001).
  • [ISSN] 1357-714X
  • [Journal-full-title] Sarcoma
  • [ISO-abbreviation] Sarcoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2694310
  •  go-up   go-down


3. Lee KH, Joo JK, Kim DY, Lee JS, Choi C, Lee JH: Mesenteric extraskeletal osteosarcoma with telangiectatic features: a case report. BMC Cancer; 2007;7:82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesenteric extraskeletal osteosarcoma with telangiectatic features: a case report.
  • BACKGROUND: Extraskeletal osteosarcoma is a rare malignant mesenchymal tumor, with a predominant occurrence in the extremities.
  • Only two cases of mesenteric extraskeletal osteosarcoma have been documented.
  • We describe an unusual case of extraskeletal osteosarcoma with telangiectatic features occurring in the mesentery.
  • Computed tomography showed a 15 x 9.7 cm heterogeneously enhancing mass, with mottled calcification and a cystic portion, occupying the left upper quadrant of the abdominal cavity.
  • The histology revealed an osteosarcoma showing osteoid formation and blood-filled spaces lined with atypical cells.
  • Despite postoperative chemotherapy, he developed a recurrent peritoneal mass and multiple lung metastases 3 months postoperatively.
  • CONCLUSION: Given the rarity of cases of mesenteric extraskeletal osteosarcoma, its biologic behavior at this location remains to be determined.
  • However, extraskeletal osteosarcoma with telangiectatic features is an uncommon entity to be recognized because of the possible fatal outcome related to the tumors.
  • [MeSH-major] Colonic Neoplasms / diagnosis. Mesentery / pathology. Osteosarcoma / diagnosis. Telangiectasis / diagnosis

  • Genetic Alliance. consumer health - Osteosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2006 Jan;30(1):119-22 [16330951.001]
  • [Cites] Histopathology. 2006 Jan;48(1):3-12 [16359532.001]
  • [Cites] Cancer. 1971 May;27(5):1121-33 [5281245.001]
  • [Cites] Cancer. 1976 Dec;38(6):2538-47 [1069603.001]
  • [Cites] Cancer. 1983 Feb 15;51(4):727-34 [6571801.001]
  • [Cites] Cancer. 1987 Sep 1;60(5):1132-42 [3475157.001]
  • [Cites] Skeletal Radiol. 2005 Oct;34(10):649-52 [15834564.001]
  • [Cites] Hum Pathol. 1991 Jun;22(6):583-90 [1864588.001]
  • [Cites] Cancer. 1993 May 15;71(10):3014-9 [8490830.001]
  • [Cites] Cancer. 1995 Dec 1;76(11):2253-9 [8635029.001]
  • [Cites] Radiographics. 1997 Sep-Oct;17(5):1205-31 [9308111.001]
  • [Cites] Am J Surg Pathol. 1998 May;22(5):588-94 [9591729.001]
  • [Cites] Cancer. 1956 Sep-Oct;9(5):1027-43 [13364888.001]
  • [Cites] Cancer. 1990 Jun 15;65(12):2762-70 [2160317.001]
  • (PMID = 17504524.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1878495
  •  go-up   go-down


Advertisement
4. Cherif F, Ben Hamida H, Mokni M, Haouet S, Khatech R, Ben Osman Dhahri A: [Extraskeletal osteosarcoma of the forearm: a case report]. Rev Chir Orthop Reparatrice Appar Mot; 2004 Sep;90(5):466-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Extraskeletal osteosarcoma of the forearm: a case report].
  • [Transliterated title] Ostéosarcome extra-squelettique de l'avant-bras: à propos d'une observation.
  • Extraskeletal osteosarcoma is a rare soft tissue tumor.
  • The pathology study of the operative specimen confirmed the diagnosis of soft tissue osteosarcoma.
  • The patient was given postoperative chemotherapy and was free of local recurrence or metastasis eighteen months after surgery.
  • [MeSH-major] Forearm. Osteosarcoma / diagnosis. Soft Tissue Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Osteosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15502770.001).
  • [ISSN] 0035-1040
  • [Journal-full-title] Revue de chirurgie orthopédique et réparatrice de l'appareil moteur
  • [ISO-abbreviation] Rev Chir Orthop Reparatrice Appar Mot
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 17
  •  go-up   go-down


5. Wei L, Song XR, Wang XW, Li M, Z uo WS: [Expression of MDR1 and GST-pi in osteosarcoma and soft tissue sarcoma and their correlation with chemotherapy resistance]. Zhonghua Zhong Liu Za Zhi; 2006 Jun;28(6):445-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of MDR1 and GST-pi in osteosarcoma and soft tissue sarcoma and their correlation with chemotherapy resistance].
  • OBJECTIVE: To explore the expression of multidrug resistance gene 1 ( MDR1), glutathione-S-transferases-pi (GST-pi) in osteosarcoma and soft tissue sarcoma tissues from 34 patients and their correlation with chemotherapy resistance.
  • METHODS: MDR1 and GST-pi expressions were analyzed by real-time fluorescence quantitative polymerase chain reaction (FQ-PCR) and flow cytometry (FCM) at mRNA and protein levels, respectively.
  • Chemotherapy sensitivity on adriamycin, cisplatinum, fluorouracil, mitomycin C, dacarbazine, vincristine, methotrexate in tumor tissues were detected by MTT assay.
  • RESULTS: The nonsensitive rates on adriamycin, cisplatinum, fluorouracil, mitomycin C, dacarbazine, vincristine, methotrexate in tumor tissues were 41.18%, 17.7%, 47.1%, 50.0%, 76.5%, 61.8% and 52.9%, respectively.
  • The expression of P-glycoprotein (P-gp) and GST-pi in tumor tissues was 1.54 and 2.58 (relative fluorescence intensity).
  • Chi2 analysis showed that there was a positive correlation between P-gp expression and drug resistance on ADM, GST-pi expression and resistance on ADM, DDP and MMC (P < 0.05).
  • There was not seen obvious correlation between expression of MDR1, GST-pi and age, gender, pathological type, tumor size in osteosarcoma and soft tissue sarcoma patients (P > 0.05).
  • The expression of GST-pi was increased in patients receiving preoperative chemotherapy.
  • CONCLUSION: Individual differences exist in chemotherapy sensitivity and expression of MDR1 and GST-pi in osteosarcoma and soft tissue sarcomas patients.
  • Chemotherapy can induce up-regulation of GST-pi protein expression.
  • Primary high expression of GST-pi is the main mechanism of resistance of osteosarcoma and soft tissue sarcomas to chemotherapy and is related to poor prognosis.
  • [MeSH-major] Bone Neoplasms / metabolism. Glutathione S-Transferase pi / biosynthesis. Osteosarcoma / metabolism. P-Glycoprotein / biosynthesis. Sarcoma / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Cisplatin / therapeutic use. Doxorubicin / therapeutic use. Drug Resistance, Multiple. Drug Resistance, Neoplasm. Female. Flow Cytometry. Follow-Up Studies. Humans. Male. Middle Aged. Mitolactol / therapeutic use. Mitomycins / therapeutic use. Prognosis. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods


6. Navid F, Santana VM, Barfield RC: Anti-GD2 antibody therapy for GD2-expressing tumors. Curr Cancer Drug Targets; 2010 Mar;10(2):200-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-GD2 antibody therapy for GD2-expressing tumors.
  • In the development of novel immune therapies for high-risk cancers, one goal is to find tumor targets that are not widely shared by normal cells.
  • This antigen is expressed on the surface of a variety of tumors for which no curative therapies exist for patients with advanced disease.
  • GD2 is also expressed on several other high-risk tumors, including those of neuroectodermal or epithelial origin, virtually all melanomas, and approximately 50% of tumor samples from osteosarcoma and soft-tissue sarcomas.
  • Because of the tumor-selective expression of this molecule, it is an attractive target for tumor-specific therapies such as antibody therapy.
  • Over the last 2 decades, several anti-GD2 antibodies have been developed.
  • To reduce both the toxicity of the antibody and the development of human anti-mouse antibodies (HAMA), research efforts have primarily focused on exploring anti-GD2 antibodies that have progressively more human elements while at the same time reducing the mouse components.
  • This review will examine antibodies currently undergoing clinical testing as well as the most recent advances to improve antibody therapy for patients with GD2-expressing tumors.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2009 Jan 1;27(1):85-91 [19047298.001]
  • [Cites] Cancer. 1992 Aug 1;70(3):633-8 [1623478.001]
  • [Cites] Cancer Immunol Immunother. 1992;35(3):199-204 [1638557.001]
  • [Cites] Cancer Res. 1992 Aug 15;52(16):4342-7 [1643631.001]
  • [Cites] Anticancer Res. 1993 Mar-Apr;13(2):331-6 [8517645.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1466-77 [8336186.001]
  • [Cites] J Clin Oncol. 1994 Jan;12(1):184-93 [8270976.001]
  • [Cites] Biochim Biophys Acta. 1994 Sep 15;1214(2):115-23 [7918590.001]
  • [Cites] Eur J Cancer. 1995;31A(2):261-7 [7718335.001]
  • [Cites] Cancer Immunol Immunother. 1995 Jul;41(1):29-36 [7641217.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2702-7 [8610104.001]
  • [Cites] J Clin Oncol. 2000 Dec 15;18(24):4077-85 [11118469.001]
  • [Cites] Mol Immunol. 2000 Nov;37(16):995-1004 [11395138.001]
  • [Cites] J Clin Oncol. 2001 Nov 15;19(22):4189-94 [11709561.001]
  • [Cites] Cancer Immunol Immunother. 2002 Apr;51(2):107-10 [11904735.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1217-23 [12006541.001]
  • [Cites] J Biol Chem. 2003 Jan 31;278(5):3466-73 [12427744.001]
  • [Cites] Int J Cancer. 2003 May 1;104(5):559-67 [12594810.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):2127-33 [15026353.001]
  • [Cites] J Nucl Med. 2004 May;45(5):867-77 [15136638.001]
  • [Cites] Int J Mol Med. 2004 Sep;14(3):383-8 [15289889.001]
  • [Cites] J Natl Cancer Inst. 2004 Aug 4;96(15):1171-80 [15292389.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3549-57 [15337804.001]
  • [Cites] Immunology. 1980 Nov;41(3):503-15 [6161872.001]
  • [Cites] J Cell Biol. 1982 Jun;93(3):576-82 [6811596.001]
  • [Cites] Cancer Res. 1984 Dec;44(12 Pt 1):5914-20 [6498849.001]
  • [Cites] Cancer Res. 1985 Jun;45(6):2642-9 [2580625.001]
  • [Cites] Cancer Res. 1986 Jan;46(1):440-3 [3940209.001]
  • [Cites] J Cell Biol. 1986 Mar;102(3):688-96 [3005335.001]
  • [Cites] Cancer Res. 1987 Jan 1;47(1):183-7 [3024814.001]
  • [Cites] J Natl Cancer Inst. 1987 Jan;78(1):45-54 [3467129.001]
  • [Cites] Cancer Res. 1987 Feb 15;47(4):1098-104 [3100030.001]
  • [Cites] J Immunol. 1987 Mar 15;138(6):1992-8 [3493293.001]
  • [Cites] J Clin Oncol. 1987 Sep;5(9):1430-40 [3625258.001]
  • [Cites] Cancer Res. 1987 Oct 15;47(20):5377-81 [3115567.001]
  • [Cites] Cancer Res. 1987 Dec 15;47(24 Pt 1):6600-5 [3499978.001]
  • [Cites] Blood. 1989 May 15;73(7):1936-41 [2653466.001]
  • [Cites] Cancer Res. 1989 Jun 1;49(11):2857-61 [2720646.001]
  • [Cites] J Immunol Methods. 1989 Dec 20;125(1-2):191-202 [2514231.001]
  • [Cites] J Immunol. 1990 Feb 15;144(4):1382-6 [2303711.001]
  • [Cites] Blood. 1990 May 15;75(10):2042-8 [2186820.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Feb 15;89(4):1428-32 [1741398.001]
  • [Cites] Hum Antibodies Hybridomas. 1992 Jan;3(1):19-24 [1576319.001]
  • [Cites] Cancer Immunol Immunother. 1996 Feb;42(2):88-92 [8620525.001]
  • [Cites] Cancer Immunol Immunother. 1995 Dec;41(6):331-8 [8635190.001]
  • [Cites] Nat Med. 1996 Sep;2(9):979-84 [8782454.001]
  • [Cites] Cancer. 1997 Jul 15;80(2):317-33 [9217046.001]
  • [Cites] Int J Cancer. 1997 Sep 26;73(1):42-9 [9334808.001]
  • [Cites] Blood. 1998 Mar 1;91(5):1706-15 [9473237.001]
  • [Cites] Int J Oncol. 1998 Jun;12(6):1299-306 [9592190.001]
  • [Cites] J Clin Oncol. 1998 Jun;16(6):2169-80 [9626218.001]
  • [Cites] J Clin Oncol. 1998 Sep;16(9):3053-60 [9738575.001]
  • [Cites] Clin Cancer Res. 1996 Dec;2(12):1951-9 [9816154.001]
  • [Cites] Clin Cancer Res. 1997 Aug;3(8):1277-88 [9815810.001]
  • [Cites] Int J Cancer. 1999 Apr 12;81(2):268-74 [10188730.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4463-73 [15483010.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10562-8 [16288049.001]
  • [Cites] Clin Cancer Res. 2005 Dec 1;11(23):8486-91 [16322312.001]
  • [Cites] Clin Cancer Res. 2006 Mar 15;12(6):1750-9 [16551859.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2885-90 [16682723.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):2331-8 [17332365.001]
  • [Cites] Blood. 2007 May 15;109(10):4245-8 [17264296.001]
  • [Cites] Oncogene. 2007 May 28;26(25):3714-33 [17530025.001]
  • [Cites] Immunol Res. 2007;39(1-3):271-8 [17917071.001]
  • [Cites] J Clin Oncol. 2007 Dec 1;25(34):5465-70 [18048828.001]
  • (PMID = 20201786.001).
  • [ISSN] 1873-5576
  • [Journal-full-title] Current cancer drug targets
  • [ISO-abbreviation] Curr Cancer Drug Targets
  • [Language] ENG
  • [Grant] None / None / / P30 CA021765-31; United States / NCI NIH HHS / CA / CA23099; United States / NCI NIH HHS / CA / CA21765; United States / NCI NIH HHS / CA / P01 CA023099; United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / P30 CA021765-31
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Anti-Idiotypic; 0 / Cancer Vaccines; 0 / Gangliosides; 65988-71-8 / ganglioside, GD2
  • [Number-of-references] 65
  • [Other-IDs] NLM/ NIHMS198855; NLM/ PMC2888262
  •  go-up   go-down


7. McCarter MD, Lewis JJ, Antonescu CR, Brennan MF: Extraskeletal osteosarcoma: analysis of outcome of a rare neoplasm. Sarcoma; 2000;4(3):119-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraskeletal osteosarcoma: analysis of outcome of a rare neoplasm.
  • Purpose. Extraskeletal osteosarcoma represents an unusual soft-tissue sarcoma that historically is reported to carry an exceptionally poor prognosis.The objectives of this study were to use a prospectively gathered sarcoma database to test the prevailing clinical bias and more accurately describe the natural history, characterize the prognostic features, estimate survival and evaluate treatment strategies for this unusual sarcoma.Patients and methods.
  • From a large database of nearly 4000 sarcomas at a single institution, 15 patients with pathologically confirmed extraskeletal osteosarcoma were analysed.Results and discussion.
  • Extraskeletal osteosarcoma usually occurs as a large, deep, high-grade lesion in the lower extremity of older patients.
  • Use of adjuvant chemotherapy or radiation therapy did not appear to influence survival, but an effect may have been missed by the relatively low numbers in each group.When matched to a comparable group of patients with stage III extremity sarcomas, there was no significant difference in overall or disease-specific survival between groups.
  • Treatment for extraskeletal osteosarcoma should follow established guidelines for treatment of soft-tissue sarcomas, with the decision regarding adjuvant therapy to be based on individual risk factors.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1982 Feb 1;49(3):480-8 [6277450.001]
  • [Cites] Cancer. 1983 Feb 15;51(4):727-34 [6571801.001]
  • [Cites] J Clin Oncol. 1996 May;14(5):1679-89 [8622088.001]
  • [Cites] Cancer. 1995 Dec 1;76(11):2253-9 [8635029.001]
  • [Cites] Cancer. 1971 May;27(5):1121-33 [5281245.001]
  • [Cites] Cancer. 1990 Jun 15;65(12):2762-70 [2160317.001]
  • [Cites] J Bone Joint Surg Br. 1979 May;61-B(2):205-8 [285933.001]
  • [Cites] Cancer. 1987 Sep 1;60(5):1132-42 [3475157.001]
  • [Cites] Am J Surg Pathol. 1998 May;22(5):588-94 [9591729.001]
  • (PMID = 18521290.001).
  • [ISSN] 1357-714X
  • [Journal-full-title] Sarcoma
  • [ISO-abbreviation] Sarcoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2395433
  •  go-up   go-down


8. Sabatier R, Bouvier C, de Pinieux G, Sarran A, Brenot-Rossi I, Pedeutour F, Chetaille B, Viens P, Weiller PJ, Bertucci F: Low-grade extraskeletal osteosarcoma of the chest wall: case report and review of literature. BMC Cancer; 2010;10:645
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade extraskeletal osteosarcoma of the chest wall: case report and review of literature.
  • BACKGROUND: Low-grade extraskeletal osteosarcomas (ESOS) are extremely rare.
  • Because of initial misdiagnosis and patient's refusal of surgery, the diagnosis was done after a 4-year history of a slowly growing mass in soft tissues, leading to a huge (30-cm diameter) calcified mass locally extended over the left chest wall.
  • Final diagnosis was helped by molecular analysis of MDM2 and CDK4 oncogenes.
  • Unfortunately, at this time, no surgical treatment was possible due to loco-regional extension, and despite chemotherapy, the patient died one year after diagnosis, five years after the first symptoms.
  • [MeSH-major] Osteosarcoma / diagnosis. Osteosarcoma / pathology. Soft Tissue Neoplasms / diagnosis. Soft Tissue Neoplasms / pathology. Thoracic Wall / pathology
  • [MeSH-minor] Adult. Cyclin-Dependent Kinase 4 / biosynthesis. Fatal Outcome. Humans. Immunohistochemistry / methods. Male. Proto-Oncogene Proteins c-mdm2 / biosynthesis. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Osteosarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Orthop Relat Res. 2000 Aug;(377):195-204 [10943202.001]
  • [Cites] Hum Pathol. 2005 Apr;36(4):439-43 [15892008.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Feb;33(2):133-40 [11793439.001]
  • [Cites] Lab Invest. 2002 Apr;82(4):365-73 [11950895.001]
  • [Cites] Skeletal Radiol. 2003 Mar;32(3):165-9 [12605283.001]
  • [Cites] J Radiol. 2003 Jan;84(1):54-6 [12637889.001]
  • [Cites] Am J Surg. 1967 Apr;113(4):537-41 [5228630.001]
  • [Cites] Acta Pathol Microbiol Scand. 1968;74(1):11-25 [5248745.001]
  • [Cites] J Bone Joint Surg Am. 1980 Dec;62(8):1274-83 [6934174.001]
  • [Cites] Am J Surg Pathol. 1985 Dec;9(12):853-71 [3000204.001]
  • [Cites] Cancer. 1987 Sep 1;60(5):1132-42 [3475157.001]
  • [Cites] Skeletal Radiol. 1989;18(6):471-4 [2814558.001]
  • [Cites] Cancer. 1990 Jun 15;65(12):2762-70 [2160317.001]
  • [Cites] Arch Pathol Lab Med. 1991 Sep;115(9):906-9 [1929787.001]
  • [Cites] Oncogene. 1999 Jan 21;18(3):783-8 [9989829.001]
  • [Cites] Ann Surg. 1953 Nov;138(5):795-800 [13092816.001]
  • [Cites] Skeletal Radiol. 2001 Jan;30(1):39-43 [11289633.001]
  • (PMID = 21106072.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.11.22 / Cyclin-Dependent Kinase 4; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  • [Other-IDs] NLM/ PMC2995804
  •  go-up   go-down


9. Serac G, Maubec E, Laissy JP, Marinho E, Abgrall S, Avril MF, Le Cesne A, Crickx B: [Metastatic extraskeletal osteosarcoma revealed by an occipital mass]. Ann Dermatol Venereol; 2008 Jun-Jul;135(6-7):499-502
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metastatic extraskeletal osteosarcoma revealed by an occipital mass].
  • [Transliterated title] Ostéosarcome extrasquelettique d'emblée métastatique révélé par une masse occipitale.
  • BACKGROUND: Extraskeletal osteosarcoma is a rare mesenchymatous tumour occurring in adults aged over 50 years and is located mainly in the limbs or retroperitoneum.
  • We report a case of metastatic extraskeletal osteosarcoma revealed by a cutaneous occipital tumour site.
  • No primary osteosarcoma was found in the bones.
  • A diagnosis was made of metastatic extraskeletal osteosarcoma.
  • Intravenous chemotherapy was given followed by radiotherapy.
  • DISCUSSION: Extraskeletal cutaneous locations of osteosarcoma are extremely rare.
  • In this patient, the immediately metastatic nature of the disease was a poor prognostic factor for this high-grade sarcoma.
  • [MeSH-major] Head and Neck Neoplasms / secondary. Osteosarcoma / secondary. Scalp. Skin Neoplasms / secondary
  • [MeSH-minor] Alopecia / etiology. Biopsy. Disease Progression. Female. Humans. Immunohistochemistry. Lung / pathology. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Magnetic Resonance Imaging. Middle Aged. Prognosis. Radiography, Thoracic. Skin / pathology. Tomography, X-Ray Computed


10. Kusuzaki K, Shinjo H, Murata H, Takeshita H, Hashiguchi S, Nozaki T, Emoto K, Ashihara T, Hirasawa Y: Relationship between doxorubicin binding ability and tumor volume decrease after chemotherapy in adult malignant soft tissue tumors in the extremities. Anticancer Res; 2000 Sep-Oct;20(5C):3813-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between doxorubicin binding ability and tumor volume decrease after chemotherapy in adult malignant soft tissue tumors in the extremities.
  • We have previously reported that the doxorubicin (DOX) binding ability detected by the DOX (or adriamycin) binding assay closely correlated with the chemosensitivity of human osteosarcomas (1).
  • We performed the present study to clarify the relationship between the DOX binding ability (%DB) and the histologic response, rate of decrease in tumor volume of malignant soft tissue tumors after preoperative chemotherapy and prognosis.
  • Nine malignant soft tissue tumors (4 liposarcomas, 3 synovial sarcomas, one malignant fibrous histiocytoma (MFH) and one extraskeletal osteosarcoma (EOS)) which arose at the extremities of adult patients were analyzed by the DOX binding assay using freshly biopsied specimens.
  • After preoperative chemotherapy including DOX or pirarubicin (THP), the rate of decrease in tumor volume was measured using magnetic resonance imaging, and the histologic response expressed as tumor necrosis to chemotherapy was also investigated.
  • All the patients, apart for one, were continuously disease-free after treatment.
  • These results suggest that in malignant soft tissue tumors, the rate of decrease in tumor volume after chemotherapy might be a better indicator for chemosensitivity than the histologic response and also that the DOX binding ability might be a good predictor for chemosensitivity before chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Doxorubicin / analogs & derivatives. Doxorubicin / pharmacokinetics. Soft Tissue Neoplasms / drug therapy. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Agents / pharmacokinetics. Antineoplastic Agents / therapeutic use. Arm. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Female. Humans. Liposarcoma / drug therapy. Liposarcoma / pathology. Magnetic Resonance Imaging. Male. Middle Aged. Osteosarcoma / drug therapy. Osteosarcoma / pathology. Sarcoma, Synovial / drug therapy. Sarcoma, Synovial / pathology. Thigh

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11268459.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 80168379AG / Doxorubicin; BG3F62OND5 / Carboplatin; D58G680W0G / pirarubicin
  •  go-up   go-down


11. Pillay P, Simango S, Govender D: Extraskeletal osteosarcoma of the scalp. Pathology; 2000 May;32(2):154-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraskeletal osteosarcoma of the scalp.
  • A rare case of extraskeletal osteosarcoma of the scalp in a 56-year-old woman is described.
  • The tumor was excised and the patient received post-operative chemotherapy.
  • Histologically, the tumor showed classical features of an osteogenic osteosarcoma with focal fibroblastic areas.
  • The patient developed metastatic disease 6 months after surgical excision.
  • [MeSH-major] Osteosarcoma / secondary. Scalp. Skin Neoplasms / pathology. Soft Tissue Neoplasms / secondary
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Cisplatin / therapeutic use. Epirubicin / therapeutic use. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Mucin-1 / analysis

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10840840.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Mucin-1; 3Z8479ZZ5X / Epirubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


12. Yang JY, Kim JM: Small cell extraskeletal osteosarcoma. Orthopedics; 2009 Mar;32(3):217
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell extraskeletal osteosarcoma.
  • Extraskeletal osteosarcoma is a rare malignant mesenchymal neoplasm that accounts for <4% of all osteosarcomas and approximately 1.2% of all soft tissue sarcomas.
  • Among the extraskeletal osteosarcomas, the small cell type is extremely rare.
  • This article describes a 31-year-old man who had small cell extraskeletal osteosarcoma arising from the semimembranosus muscle.
  • The results were reported as a malignant small round cell tumor, consistent with an extraskeletal Ewing's sarcoma or primitive neuroectodermal tumor.
  • The patient refused neoadjuvant chemotherapy.
  • The final diagnosis was small cell extraskeletal osteosarcoma.
  • Adjuvant chemotherapy was performed using doxorubicin, ifosfamide, and cisplatin together with a total of 60 Gy of radiation therapy.
  • We performed chest computed tomography, magnetic resonance imaging, and positron emission tomography-computed tomography.
  • [MeSH-major] Muscle Neoplasms / pathology. Osteosarcoma / pathology. Sarcoma, Small Cell / pathology
  • [MeSH-minor] Adult. Antigens, CD / analysis. Biomarkers, Tumor / analysis. Cell Adhesion Molecules / analysis. Combined Modality Therapy. Disease-Free Survival. Humans. Male. Muscle, Skeletal / pathology

  • Genetic Alliance. consumer health - Osteosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19309043.001).
  • [ISSN] 1938-2367
  • [Journal-full-title] Orthopedics
  • [ISO-abbreviation] Orthopedics
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules
  •  go-up   go-down


13. Oonuma M, Hatori M, Hosaka M, Kokubun S: Extraskeletal osteosarcoma arising in the buttock. Ups J Med Sci; 2001;106(3):211-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraskeletal osteosarcoma arising in the buttock.
  • Extraskeletal osteosarcoma is a rare sarcoma that accounts for about 1% of malignant soft tissue tumours.
  • We report an very unusual case of a small-size extraskeletal osteosarcoma arising in the superficial subcutaneous region of the buttock.
  • 10 mm mass in the subcutaneous tissue.
  • The tumour was diagnosed as extraskeletal osteosarcoma.
  • Chemotherapy with Rosen T-20 was administered to the patient.
  • Its superficial location, very small size, wide excision, and chemotherapy were thought to contribute to her long survival.
  • [MeSH-major] Buttocks. Osteosarcoma / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12166514.001).
  • [ISSN] 0300-9734
  • [Journal-full-title] Upsala journal of medical sciences
  • [ISO-abbreviation] Ups. J. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Sweden
  •  go-up   go-down


14. Kajihara M, Sugawara Y, Miki H, Mochizuki T, Kidani T, Sakayama K: Tl-201 and Tc-99m HMDP scintigraphic findings in extraskeletal osteosarcoma. Clin Nucl Med; 2005 May;30(5):356-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tl-201 and Tc-99m HMDP scintigraphic findings in extraskeletal osteosarcoma.
  • Extraskeletal osteosarcoma is an extremely rare high-grade malignant soft tissue tumor, which accounts for approximately 4% of osteosarcomas and less than 1% of all soft tissue sarcomas.
  • We report a biopsy-proven case of extraskeletal osteosarcoma in which the bone and thallium scans were found to be useful in monitoring chemotherapy response.
  • The Tc-99m HMDP bone scan revealed increased extraskeletal uptake in the tumor.
  • [MeSH-major] Muscle Neoplasms / radionuclide imaging. Osteosarcoma / radionuclide imaging. Soft Tissue Neoplasms / radionuclide imaging. Technetium Tc 99m Medronate / analogs & derivatives. Thallium

  • Genetic Alliance. consumer health - Osteosarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. THALLIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. THALLOUS CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15827415.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 72945-61-0 / technetium Tc 99m hydroxymethylene diphosphonate; 7791-12-0 / thallium chloride; AD84R52XLF / Thallium; X89XV46R07 / Technetium Tc 99m Medronate
  •  go-up   go-down


15. Lee S, Lee MR, Lee SJ, Ahn HK, Yi J, Yi SY, Seo SW, Sung KS, Park JO, Lee J: Extraosseous osteosarcoma: single institutional experience in Korea. Asia Pac J Clin Oncol; 2010 Jun;6(2):126-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraosseous osteosarcoma: single institutional experience in Korea.
  • AIM: Extraosseous osteosarcoma (EOO) is a rare soft tissue form of osteosarcoma without involvement of the skeletal system.
  • Due to the rarity of disease, its clinical features and optimal treatment are yet to be defined.
  • METHODS: Between 1 January 1999 and 30 June 2008 ten patients were pathologically confirmed with extra-skeletal osteosarcoma.
  • RESULTS: The anatomical distribution of the osteosarcomas was as follows: lower extremities (n = 3), upper extremities (n = 2), breast (n = 2), lung (n = 1), cheek (n = 1) and retroperitoneum (n = 1).
  • One patient, who received six cycles of adjuvant doxorubicin and cisplatin chemotherapy was alive in remission at 42.6 months.
  • However, all three patients who received curative resection but no postoperative radiotherapy or chemotherapy died of the disease at 10.7, 11.1 and 15.6 months after surgery.
  • The median time to failure was only 4.4 months (95% CI, 0.6, 8.2 months) and the median survival time of all patients was only 11.1 months (95% CI, 5.6, 16.6 months).
  • At the time of analysis, seven patients were dead and all died of the disease recurrence.
  • CONCLUSION: EOO should be treated as a soft tissue sarcoma with aggressive behavior and multimodality treatment should be actively sought to improve treatment outcome.
  • The impact of adjuvant chemotherapy on survival of EOO needs further investigation.
  • [MeSH-major] Osteosarcoma / therapy. Soft Tissue Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Bone Neoplasms / pathology. Bone Neoplasms / therapy. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Humans. Korea. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Osteosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20565425.001).
  • [ISSN] 1743-7563
  • [Journal-full-title] Asia-Pacific journal of clinical oncology
  • [ISO-abbreviation] Asia Pac J Clin Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


16. Wodowski K, Hill DA, Pappo AS, Shochat SJ, Kun LE, Spunt SL: A chemosensitive pediatric extraosseous osteosarcoma: case report and review of the literature. J Pediatr Hematol Oncol; 2003 Jan;25(1):73-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A chemosensitive pediatric extraosseous osteosarcoma: case report and review of the literature.
  • Osteosarcoma arising in soft tissues is exceedingly rare in children.
  • The tumor most often affects older adults, involves the lower extremity, responds poorly to chemotherapy, and carries a grave prognosis.
  • The authors describe a 12-year-old girl with an extraosseous osteosarcoma of the left sternocleidomastoid muscle with pulmonary metastases.
  • The patient responded well to neoadjuvant chemotherapy and remains disease-free nearly 3 years after her initial diagnosis.
  • Children with extraosseous osteosarcoma may have a more favorable response to treatment than adults; thus, a curative approach using combined modality therapy appears warranted.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lung Neoplasms / drug therapy. Osteosarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Doxorubicin / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Male. Neoadjuvant Therapy. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for extraosseous osteosarcoma .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12544778.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 23099; United States / NCI NIH HHS / CA / P30 CA 21765
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  • [Number-of-references] 36
  •  go-up   go-down


17. Ahmad SA, Patel SR, Ballo MT, Baker TP, Yasko AW, Wang X, Feig BW, Hunt KK, Lin PP, Weber KL, Chen LL, Zagars GK, Pollock RE, Benjamin RS, Pisters PW: Extraosseous osteosarcoma: response to treatment and long-term outcome. J Clin Oncol; 2002 Jan 15;20(2):521-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraosseous osteosarcoma: response to treatment and long-term outcome.
  • PURPOSE: To evaluate the clinicopathologic features of extraosseous osteosarcoma (EOO), a rare soft tissue form of osteosarcoma, and to examine its response to multimodality therapy.
  • Anderson Cancer Center between 1960 and 1999 were reviewed for clinicopathologic factors, treatment, and outcome.
  • Twenty-seven patients with measurable and assessable disease were treated with doxorubicin-based chemotherapy (median doxorubicin starting dose, 75 mg/m(2); median number of cycles, four).
  • CONCLUSION: EOO should be considered clinically and therapeutically distinct from osseous osteosarcoma.
  • Radiographic response rates and pathologic complete response rates to doxorubicin-based systemic therapy are low.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasm Recurrence, Local. Osteosarcoma / drug therapy. Osteosarcoma / surgery. Soft Tissue Neoplasms / drug therapy. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Osteosarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11786582.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin
  •  go-up   go-down


18. Torigoe T, Yazawa Y, Takagi T, Terakado A, Kurosawa H: Extraskeletal osteosarcoma in Japan: multiinstitutional study of 20 patients from the Japanese Musculoskeletal Oncology Group. J Orthop Sci; 2007 Sep;12(5):424-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraskeletal osteosarcoma in Japan: multiinstitutional study of 20 patients from the Japanese Musculoskeletal Oncology Group.
  • BACKGROUND: The clinical features of extraskeletal osteosarcoma are not well known.
  • Unlike osteosarcoma of the bone, the efficacy of chemotherapy for extraskeletal osteosarcoma has not been established yet.
  • METHODS: A multiinstitutional study of extraskeletal osteosarcoma was conducted.
  • Altogether, 15 patients received chemotherapy, of whom 11 had evaluable responses as follows: complete response in none, partial response in 5 patients, and no change or progressive disease in 6 patients, with a response rate of 45%.
  • CONCLUSIONS: Among the patients with extraskeletal osteosarcoma, both the 5-year survival rate and the chemotherapy response rate tended to improve in this study in comparison to the findings published in previous reports.
  • As a result, we believe that treatment regimens that include systemic chemotherapy may be able to improve the prognosis in patients with extraskeletal osteosarcoma.
  • [MeSH-major] Osteosarcoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. Humans. Japan / epidemiology. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Osteosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17909926.001).
  • [ISSN] 0949-2658
  • [Journal-full-title] Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association
  • [ISO-abbreviation] J Orthop Sci
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Japan
  •  go-up   go-down


19. Goldstein-Jackson SY, Gosheger G, Delling G, Berdel WE, Exner GU, Jundt G, Machatschek JN, Zoubek A, Jürgens H, Bielack SS, Cooperative Osteosarcoma Study Group COSS: Extraskeletal osteosarcoma has a favourable prognosis when treated like conventional osteosarcoma. J Cancer Res Clin Oncol; 2005 Aug;131(8):520-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraskeletal osteosarcoma has a favourable prognosis when treated like conventional osteosarcoma.
  • PURPOSE: The aims of this analysis were to investigate the clinical features of extraskeletal osteosarcoma (ESOS) and examine the outcome after multi-modal therapy.
  • METHODS: The co-operative osteosarcoma study-group database was searched for patients with extraskeletal osteosarcoma.
  • Eligible patients were included in a retrospective analysis of patient, tumour and treatment related variables and outcome.
  • As for conventional osteosarcoma, scheduled treatment included surgery and multi-agent chemotherapy.
  • This may be due to the combination of multi-agent chemotherapy with surgery, and we recommend this approach in the treatment of ESOS.
  • [MeSH-major] Osteosarcoma / diagnosis. Osteosarcoma / therapy
  • [MeSH-minor] Adolescent. Adult. Bone Neoplasms / diagnosis. Bone Neoplasms / therapy. Chemotherapy, Adjuvant. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Osteosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Radiol. 1991 Feb;64(758):171-2 [1900726.001]
  • [Cites] Skeletal Radiol. 2001 Jan;30(1):39-43 [11289633.001]
  • [Cites] Klin Padiatr. 1999 Jul-Aug;211(4):260-70 [10472560.001]
  • [Cites] Am J Surg Pathol. 1998 May;22(5):588-94 [9591729.001]
  • [Cites] Skeletal Radiol. 2003 Mar;32(3):165-9 [12605283.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):776-90 [11821461.001]
  • [Cites] Cancer Chemother Rep. 1966 May;50(4):173-218 [5938250.001]
  • [Cites] Ann Oncol. 1998 Aug;9(8):893-9 [9789613.001]
  • [Cites] Cancer. 1983 Feb 15;51(4):727-34 [6571801.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 Jan;25(1):73-7 [12544778.001]
  • [Cites] Cancer. 1995 Dec 1;76(11):2253-9 [8635029.001]
  • [Cites] J Clin Oncol. 1988 Feb;6(2):329-37 [2448428.001]
  • [Cites] J Clin Oncol. 2002 Jan 15;20(2):521-7 [11786582.001]
  • [Cites] Sarcoma. 2000;4(3):119-23 [18521290.001]
  • [Cites] Am J Surg Pathol. 1998 Aug;22(8):925-33 [9706972.001]
  • [Cites] J Clin Oncol. 1984 Jun;2(6):617-24 [6202851.001]
  • [Cites] J Am Acad Dermatol. 2003 Jul;49(1):124-7 [12833024.001]
  • [Cites] Cancer. 1990 Jun 15;65(12):2762-70 [2160317.001]
  • [Cites] Cancer. 1987 Sep 1;60(5):1132-42 [3475157.001]
  • [Cites] Pathologe. 1983 May;4(3):135-41 [6576329.001]
  • [Cites] J Bone Joint Surg Am. 1998 May;80(5):725-9 [9611034.001]
  • (PMID = 15918046.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


20. Hulse N, Paul AS: Soft tissue osteosarcoma: a case report. Acta Orthop Belg; 2006 Dec;72(6):783-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft tissue osteosarcoma: a case report.
  • Osteosarcomas arising from extraskeletal locations are extremely rare and their true prevalence is unknown.
  • We describe a case of soft tissue-origin-osteosarcoma arising from the vastus medialis muscle in a 58-year old woman.
  • The possibility of a malignant tumour was not suspected initially and she was referred to a specialist unit only one year after the onset of the swelling.
  • She was successfully treated with a surgical resection, chemotherapy and radiotherapy.
  • Because of the rarity of the tumour, a high degree of suspicion is required to make an early diagnosis.
  • The differential diagnosis of a soft tissue mass located in the thigh in a patient over the age of 40 years, should include extraskeletal osteosarcoma.
  • [MeSH-major] Osteosarcoma / diagnosis. Soft Tissue Neoplasms / diagnosis
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Thigh

  • Genetic Alliance. consumer health - Osteosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17260622.001).
  • [ISSN] 0001-6462
  • [Journal-full-title] Acta orthopaedica Belgica
  • [ISO-abbreviation] Acta Orthop Belg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


21. Paulides M, Stöhr W, Bielack S, Jürgens H, Koscielniak E, Klingebiel T, Zimmermann R, Stachel D, Langer T, Beck JD: Prospective evaluation of hepatitis B, C and HIV infections as possible sequelae of antineoplastic treatment in paediatric sarcoma patients: a report from the Late Effects Surveillance System. Oncol Rep; 2006 Mar;15(3):687-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective evaluation of hepatitis B, C and HIV infections as possible sequelae of antineoplastic treatment in paediatric sarcoma patients: a report from the Late Effects Surveillance System.
  • Cancer therapy and supportive measures entail the risk of infection with hepatitis B (HBV), hepatitis C (HCV) or human immunodeficiency virus (HIV).
  • The objective of this analysis was to establish the incidence of infections with these viruses during antineoplastic treatment in our paediatric sarcoma patients, who are being followed-up within the Late Effects Surveillance System (LESS), which prospectively registers sequelae of therapy for Ewing's-, soft tissue- and osteosarcoma in patients treated in Germany, Austria and Switzerland within the trials EICESS-92/EURO-E.W.I.N.G.
  • We studied 264 eligible relapse-free paediatric patients [median age at diagnosis 14.3 (IQR 11.1-16.4) years], treated from January 7, 1998 until April 24, 2004.
  • According to the LESS protocol, serological examinations for HBV, HCV and HIV were scheduled 4 weeks and 6 months after cessation of antineoplastic treatment.
  • None of the patients was reported to have acquired HBV, HCV or HIV during antineoplastic treatment.
  • Blood donor screening and prophylactic measures employed in Germany, Austria and Switzerland to prevent infections of cancer patients with HBV, HCV and HIV seem to be very effective, having fully prevented new infections in this large cohort of paediatric sarcoma patients.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Sarcoma / drug therapy. Virus Diseases / etiology


22. Sirikulchayanonta V, Jaovisidha S: Soft tissue telangiectatic osteosarcoma in a young patient: imaging and immunostains. Skeletal Radiol; 2005 May;34(5):295-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft tissue telangiectatic osteosarcoma in a young patient: imaging and immunostains.
  • Telangiectatic osteosarcoma of the soft tissue is rare and generally affects adults older than 50 years of age.
  • We present the case of a 17-year-old male who developed a mass in the right thigh.
  • The CT and MRI findings suggested a malignant hemorrhagic tumor without discernable osteoid matrix.
  • Differential diagnosis included various hemorrhagic mesenchymal tumors.
  • Surgery and adjuvant chemotherapy were applied and the patient survives to the time of writing after 30 months of follow-up without recurrence or metastasis.
  • [MeSH-major] Osteosarcoma / diagnosis. Soft Tissue Neoplasms / diagnosis. Thigh / pathology
  • [MeSH-minor] Adolescent. Antibiotics, Antineoplastic / therapeutic use. Chemotherapy, Adjuvant. Diagnosis, Differential. Doxorubicin / therapeutic use. Humans. Magnetic Resonance Imaging. Male. Osteocalcin / blood. Radiography. Telangiectasis

  • Genetic Alliance. consumer health - Osteosarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1992 Aug 1;70(3):619-24 [1320449.001]
  • [Cites] Eur J Histochem. 1996;40(3):189-98 [8922947.001]
  • [Cites] Cancer. 1983 Feb 15;51(4):727-34 [6571801.001]
  • [Cites] Hum Pathol. 1991 Jun;22(6):583-90 [1864588.001]
  • [Cites] Cancer. 1993 May 15;71(10):3014-9 [8490830.001]
  • [Cites] Cancer. 1995 Dec 1;76(11):2253-9 [8635029.001]
  • [Cites] Nihon Igaku Hoshasen Gakkai Zasshi. 1992 Aug 25;52(8):1110-5 [1408681.001]
  • [Cites] Hum Pathol. 1999 Jan;30(1):32-8 [9923924.001]
  • [Cites] Crit Rev Diagn Imaging. 1994;35(5):379-483 [7832987.001]
  • [Cites] Radiographics. 1993 Jul;13(4):853-84 [8356273.001]
  • [Cites] Radiology. 1990 Jun;175(3):779-82 [2160676.001]
  • [Cites] J Bone Joint Surg Br. 1979 May;61-B(2):205-8 [285933.001]
  • [Cites] Cancer. 1990 Jun 15;65(12):2762-70 [2160317.001]
  • [Cites] Skeletal Radiol. 1997 Dec;26(12):732-6 [9453109.001]
  • [Cites] Radiology. 2003 Nov;229(2):545-53 [14512511.001]
  • [Cites] Histopathology. 1998 Aug;33(2):185-6 [9762554.001]
  • [Cites] J Comput Assist Tomogr. 1993 May-Jun;17(3):414-7 [8491903.001]
  • [Cites] Cancer. 1987 Sep 1;60(5):1132-42 [3475157.001]
  • (PMID = 15570422.001).
  • [ISSN] 0364-2348
  • [Journal-full-title] Skeletal radiology
  • [ISO-abbreviation] Skeletal Radiol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 104982-03-8 / Osteocalcin; 80168379AG / Doxorubicin
  •  go-up   go-down


23. Paulides M, Dörr HG, Stöhr W, Bielack S, Koscielniak E, Klingebiel T, Jürgens H, Bölling T, Willich N, Sauer R, Langer T, Beck JD, Late Effects Surveillance System: Thyroid function in paediatric and young adult patients after sarcoma therapy: a report from the Late Effects Surveillance System. Clin Endocrinol (Oxf); 2007 May;66(5):727-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid function in paediatric and young adult patients after sarcoma therapy: a report from the Late Effects Surveillance System.
  • OBJECTIVE: The role of chemotherapy in thyroid sequelae after cancer treatment has not been studied systematically, especially in sarcoma patients.
  • The aim of this study was to determine the incidence of post-therapeutic thyroid disorders and their contributing factors in a cohort of paediatric sarcoma patients.
  • DESIGN: Late effects of sarcoma treatment have been collected prospectively within the Late Effects Surveillance System (LESS) in Germany, Austria and Switzerland since 1998.
  • PATIENTS: We studied 340 relapse-free paediatric patients (median age at diagnosis 12.2 [interquartile range (IQR) = 7.3-15.6 years] treated for osteosarcoma, soft tissue sarcoma or Ewing's sarcoma within the COSS-96, CWS-96/CWS-2002P or EICESS-92/EURO-E.W.I.N.G.
  • -99 therapy trials.
  • In addition to polychemotherapy, 127 patients were irradiated (mean cumulative dose 47 +/- 9.7 Gy), including 51 patients with irradiation to the head/neck region.
  • We also found a significant association between raised TSH levels and treatment with trofosfamide (P = 0.008) or idarubicin (P = 0.037) (n = 250).
  • Even without head/neck irradiation, we found an increased proportion of patients with thyroid disorders, possibly as a result of chemotherapy.
  • [MeSH-major] Sarcoma / therapy. Thyroid Diseases / physiopathology. Thyroid Gland / physiopathology
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Child. Cyclophosphamide / adverse effects. Cyclophosphamide / analogs & derivatives. Dactinomycin / adverse effects. Female. Follow-Up Studies. Humans. Ifosfamide / adverse effects. Ifosfamide / therapeutic use. Incidence. Male. Multivariate Analysis. Thyroid Function Tests. Thyrotropin / blood. Thyroxine / blood. Thyroxine / therapeutic use. Vincristine / adverse effects

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nat Clin Pract Endocrinol Metab. 2007 Dec;3(12):804-5 [17895866.001]
  • (PMID = 17381483.001).
  • [ISSN] 0300-0664
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; 9002-71-5 / Thyrotropin; H64JRU6GJ0 / trofosfamide; Q51BO43MG4 / Thyroxine; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


24. Pásztélyi Z, Schuler D, Czvenits E: Practice guidelines in pediatric hematooncology: implementation and survey. A possible way for medical quality assurance. Pediatr Hematol Oncol; 2000 Dec;17(8):679-85
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Hungarian Pediatric Oncology Working Group intended to change the practice of prescribing diagnostic tests as well as to examine the possibility of introducing indicators about the time factors of medical care.
  • The examined time factors were the length of elapsed time from admittance to treatment and the length of hospital stay for different reasons (diagnosis, treatment, complications).
  • Included into this study are the new cases of 5 common groups of malignancies (acute lymphoblastic leukemia and non-Hodgkin lymphoma, osteosarcoma, soft tissue sarcoma, Wilms tumor, neuroblastoma) for a study period of 1 year.
  • Using the data provided by this questionnaire, a renewal of the protocols for each disease was made three times during the whole study period.
  • The authors intended to use their time indicators for benchmarking, to make a comparison possible between centers concerning the length of treatment, occurrence of complications, and delays in chemotherapy.
  • However, the examination of the time indicators in the most frequent disease (acute lymphoblastic leukemia, n = 73) showed inverse correlation between the number of admissions per year per center and the length of time elapsed up to the beginning of treatment.
  • This points to a need for better cooperation in small centers at the initial phase of the diagnosis.
  • [MeSH-minor] Follow-Up Studies. Humans. Hungary. Neoplasms / drug therapy. Quality Assurance, Health Care. Surveys and Questionnaires. Time Factors

  • MedlinePlus Health Information. consumer health - Children's Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11127400.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


25. Skubitz KM: Phase II trial of pegylated-liposomal doxorubicin (Doxil) in sarcoma. Cancer Invest; 2003 Apr;21(2):167-76
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of pegylated-liposomal doxorubicin (Doxil) in sarcoma.
  • We performed a phase II study of Doxil in sarcoma.
  • The patient population was primarily previously treated or had diagnoses considered unresponsive to chemotherapy.
  • Treatment was generally well tolerated.
  • Of 214 evaluable treatment courses in 47 patients, toxicities were mild and similar to previous reports, but dose reduction was common.
  • There were: 6 osteosarcomas, 3 Ewings, 1 extraosseous osteosarcoma, 1 chondrosarcoma, 2 alveolar soft part sarcomas, 15 gastrointestinal stromal cell tumors (GIST), and 19 other soft tissue sarcomas.
  • Three of the 47 patients received a CR or PR, although 15 of the 47 patients were felt to have derived clinical benefit from the treatment.
  • These data suggest that pegylated-liposomal doxorubicin has activity in this population of poor prognosis sarcoma and that this treatment is associated with modest toxicity.
  • [MeSH-major] Doxorubicin / adverse effects. Doxorubicin / therapeutic use. Sarcoma / drug therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Blood Cell Count. Bone Neoplasms / drug therapy. Drug Carriers. Fatigue / chemically induced. Fatigue / epidemiology. Female. Humans. Liposomes. Male. Middle Aged. Nausea / chemically induced. Nausea / epidemiology. Osteosarcoma / drug therapy. Skin Diseases / chemically induced. Stroke Volume / drug effects

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Invest. 2003 Apr;21(2):321-2 [12743996.001]
  • (PMID = 12743981.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Carriers; 0 / Liposomes; 80168379AG / Doxorubicin
  •  go-up   go-down


26. Lejeune FJ, Pujol N, Liénard D, Mosimann F, Raffoul W, Genton A, Guillou L, Landry M, Chassot PG, Chiolero R, Bischof-Delaloye A, Leyvraz S, Mirimanoff RO, Bejkos D, Leyvraz PF: Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities. Eur J Surg Oncol; 2000 Nov;26(7):669-78
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities.
  • AIMS: Patients with non-resectable soft tissue sarcomas of the extremities do not live longer if they are treated by amputation or disarticulation.
  • In order to avoid major amputations, we tested isolated limb perfusion (ILP) with tumour necrosis factor alpha (TNF)+melphalan+/-interferon-gamma (IFN) as a pre-operative, neoadjuvant limb salvage treatment.
  • The AJCC stage was IIA in four patients, III in seven and IV in 11.
  • Thirteen cases were recurrent or progressive after previous therapy; five tumours had a diameter >/=20 cm, and four were multiple or regionally metastatic.
  • There were six malignant fibrous histiocytomas, five liposarcomas, four malignant peripheral nerve sheath tumours, three rhabdomyosarcomas, two leiomyosarcomas, one recurrent extraskeletal osteosarcoma and one angiosarcoma.
  • All patients had fever for 24 hours but only one developed a reversible grade 3 distributive shock syndrome with no sequelae.
  • Seventeen patients (77%) underwent limb-sparing resection of the tumour remnants after a median time of 3.4 months: 10 resections were intracompartmental and seven extracompartmental.
  • Adjuvant chemotherapy was given to eight patients and radiotherapy to six.
  • The median disease free and overall survival times have been >12.5 and 18.7 months respectively: this is similar to the outcome after primary amputations for similar cases.
  • CONCLUSION: ILP with TNF and chemotherapy is an efficient limb sparing neoadjuvant therapy for a priori non-resectable limb soft tissue sarcomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Leg / surgery. Sarcoma / drug therapy. Sarcoma / surgery. Soft Tissue Neoplasms / drug therapy. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Chemotherapy, Cancer, Regional Perfusion. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Interferon-gamma / administration & dosage. Interferon-gamma / adverse effects. Male. Melphalan / administration & dosage. Melphalan / adverse effects. Middle Aged. Neoadjuvant Therapy. Neoplasm Recurrence, Local / surgery. Radiotherapy, Adjuvant. Salvage Therapy. Survival Analysis. Tumor Necrosis Factor-alpha / administration & dosage. Tumor Necrosis Factor-alpha / adverse effects

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Harcourt Publishers Ltd.
  • (PMID = 11078614.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha; 80168379AG / Doxorubicin; 82115-62-6 / Interferon-gamma; Q41OR9510P / Melphalan; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


27. Lubin M, Lubin A: Selective killing of tumors deficient in methylthioadenosine phosphorylase: a novel strategy. PLoS One; 2009 May 29;4(5):e5735
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MTAP and CDKN2A are homozygously co-deleted, with a frequency of 35 to 70%, in lung and pancreatic cancer, glioblastoma, osteosarcoma, soft-tissue sarcoma, mesothelioma, and T-cell acute lymphoblastic leukemia.
  • This distinct difference between normal MTAP-positive cells and tumor MTAP-negative cells led to several proposals for therapy.
  • PRINCIPAL FINDINGS: We show that this combination treatment--adenine analog plus MTA--kills MTAP-negative A549 lung tumor cells, while MTAP-positive human fibroblasts (HF) are protected.
  • The combination of MTA with 5-FU or 6-TG, in the treatment of MTAP-negative tumors, may produce a significantly improved therapeutic index.
  • [MeSH-major] Drug Screening Assays, Antitumor / methods. Neoplasms / enzymology. Neoplasms / pathology. Purine-Nucleoside Phosphorylase / metabolism
  • [MeSH-minor] Adenine / analogs & derivatives. Adenine / pharmacology. Cell Death / drug effects. Cell Line. Coculture Techniques. Deoxyadenosines / pharmacology. Fluorouracil / pharmacology. Humans. Thioguanine / pharmacology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. THIOGUANINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2003 Aug;163(2):683-90 [12875987.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):2108-13 [12796375.001]
  • [Cites] Biochem J. 1969 Nov;115(2):241-7 [5378381.001]
  • [Cites] J Med Chem. 1974 Nov;17(11):1197-207 [4412000.001]
  • [Cites] Biochem Biophys Res Commun. 1978 Jul 14;83(1):27-35 [100109.001]
  • [Cites] J Natl Cancer Inst. 1980 Jan;64(1):69-72 [6928048.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 Feb;78(2):1219-23 [6785752.001]
  • [Cites] Biochem J. 1981 Jan 15;194(1):79-89 [7305994.001]
  • [Cites] Biochem Pharmacol. 1982 Feb 1;31(3):277-88 [6803807.001]
  • [Cites] Biochem Pharmacol. 1983 Jan 15;32(2):199-206 [6870949.001]
  • [Cites] Biochem Pharmacol. 1983 Oct 1;32(19):2915-20 [6626263.001]
  • [Cites] J Biol Chem. 1984 May 10;259(9):5465-71 [6425290.001]
  • [Cites] Exp Hematol. 1984 Dec;12(11):867-71 [6510486.001]
  • [Cites] Biochem Pharmacol. 1985 Feb 1;34(3):361-7 [3918539.001]
  • [Cites] Adv Exp Med Biol. 1988;250:229-38 [3151228.001]
  • [Cites] Leuk Res. 1990;14(11-12):1061-6 [2280604.001]
  • [Cites] Cancer Res. 1991 Jun 15;51(12):3193-7 [1904005.001]
  • [Cites] J Clin Oncol. 1993 Jan;11(1):5-14 [8418242.001]
  • [Cites] Cancer Res. 1993 Mar 1;53(5):1098-101 [8382555.001]
  • [Cites] Nat Genet. 1994 Sep;8(1):27-32 [7726912.001]
  • [Cites] Oncogene. 1995 Mar 2;10(5):827-33 [7898924.001]
  • [Cites] Blood. 1996 Oct 15;88(8):3083-90 [8874207.001]
  • [Cites] Cancer. 1951 May;4(3):549-69 [14839611.001]
  • [Cites] Bioorg Med Chem Lett. 2005 Jun 2;15(11):2829-33 [15911263.001]
  • [Cites] Curr Top Med Chem. 2005;5(13):1259-74 [16305530.001]
  • [Cites] Mol Cancer Ther. 2005 Dec;4(12):1860-6 [16373701.001]
  • [Cites] J Biochem. 2006 Jan;139(1):1-9 [16428313.001]
  • [Cites] Blood. 2006 Feb 1;107(3):898-903 [16234352.001]
  • [Cites] J Biol Chem. 2007 Jul 20;282(29):21477-86 [17548352.001]
  • [Cites] Antimicrob Agents Chemother. 2008 Jan;52(1):211-9 [17954686.001]
  • [Cites] J Biol Chem. 2008 Jun 6;283(23):16135-46 [18367445.001]
  • [Cites] Invest New Drugs. 2009 Feb;27(1):75-81 [18618081.001]
  • [Cites] J Hepatol. 2001 Mar;34(3):386-94 [11322199.001]
  • [Cites] Oncol Res. 2004;14(7-8):373-9 [15301428.001]
  • [Cites] Clin Cancer Res. 2002 Mar;8(3):782-7 [11895909.001]
  • [Cites] J Pharmacol Exp Ther. 2003 Mar;304(3):1280-4 [12604707.001]
  • [ErratumIn] PLoS One. 2010;5(4). doi: 10.1371/annotation/54fad81d-c975-4b30-bb2b-249650ec3d66
  • (PMID = 19478948.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Deoxyadenosines; 4754-39-6 / 5'-deoxyadenosine; EC 2.4.2.1 / Purine-Nucleoside Phosphorylase; EC 2.4.2.28 / 5'-methylthioadenosine phosphorylase; FTK8U1GZNX / Thioguanine; JAC85A2161 / Adenine; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2684647
  •  go-up   go-down


28. Langer T, Stöhr W, Paulides M, Kremers A, Dörr HG, Göbel U, Beck JD: Prospective multicenter registration of major late sequelae in sarcoma patients using the Late Effects Surveillance System (LESS). Klin Padiatr; 2005 May-Jun;217(3):176-81
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective multicenter registration of major late sequelae in sarcoma patients using the Late Effects Surveillance System (LESS).
  • BACKGROUND: Late effects become progressively more important for the evaluation of therapeutic success in paediatric oncology.
  • Thus, in 1998, the Late Effects Surveillance System (LESS) started to register and assess multicentrally, prospectively and longitudinally late effects of treatment for the group of Ewing's, soft tissue- and osteosarcoma patients.
  • PATIENTS AND METHODS: The yearly results of the follow-up examinations of 785 Ewing's, soft tissue- and osteosarcoma patients, who were treated from 1.1.1998 until 31.12.2001, were prompted and assessed conforming to the guidelines developed by the LESS-study.
  • Only 8 % of patients eligible for the LESS-study were cared for in non-cooperating facilities.
  • Thus, the basis has been set for the development of risk-oriented strategies for intervention and for the further improvement of the follow-up of major late effects in sarcoma patients.
  • [MeSH-major] Population Surveillance. Registries. Sarcoma / mortality. Sarcoma / therapy. Survivors
  • [MeSH-minor] Adolescent. Adult. Age Factors. Antineoplastic Combined Chemotherapy Protocols. Bone Neoplasms / complications. Bone Neoplasms / drug therapy. Bone Neoplasms / mortality. Bone Neoplasms / therapy. Child. Clinical Trials as Topic. Follow-Up Studies. Germany. Humans. Multicenter Studies as Topic. Osteosarcoma / complications. Osteosarcoma / drug therapy. Osteosarcoma / mortality. Osteosarcoma / therapy. Practice Guidelines as Topic. Prospective Studies. Quality of Life. Sarcoma, Ewing / complications. Sarcoma, Ewing / drug therapy. Sarcoma, Ewing / mortality. Sarcoma, Ewing / therapy. Surveys and Questionnaires. Time Factors

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15858710.001).
  • [ISSN] 0300-8630
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


29. Momoi H, Wada Y, Sarumaru S, Tamaki N, Gomi T, Kanaya S, Katayama T, Ootoshi M, Fukumoto M: Primary osteosarcoma of the breast. Breast Cancer; 2004;11(4):396-400
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary osteosarcoma of the breast.
  • We report a case of primary osteosarcoma of the breast, which is a rare histological type of all breast tumors.
  • Histologically, the excised tumor was consistent with extraskeletal osteosarcoma of the breast accompanied by lymph node metastses.
  • In spite of adjuvant chemotherapy, the patient suffered a local recurrence four months later and died of aggressive multiple metastases 7 months after surgery.
  • [MeSH-major] Bone Neoplasms / diagnosis. Breast Neoplasms / diagnosis. Neoplasm Recurrence, Local / diagnosis. Osteosarcoma / diagnosis
  • [MeSH-minor] Combined Modality Therapy. Diagnosis, Differential. Fatal Outcome. Female. Humans. Middle Aged. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15604996.001).
  • [ISSN] 1340-6868
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


30. Salamanca J, Dhimes P, Pinedo F, Gómez de la Fuente E, Pérez Espejo G, Martínez-Tello FJ: Extraskeletal cutaneous chondroblastic osteosarcoma: a case report. J Cutan Pathol; 2008 Feb;35(2):231-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraskeletal cutaneous chondroblastic osteosarcoma: a case report.
  • Extraskeletal osteosarcoma is an uncommon neoplasm that usually arises in the deep soft tissues, especially in the lower extremities, with rare cases involving the subcutis or dermis.
  • An incisional skin biopsy showed a well-defined, but non-encapsulated neoplasm, characterized by extensive cartilage with marked cellularity, atypia and high mitotic activity, involving the dermis and subcutis.
  • Although osteoid or bone was not observed, a diagnosis of cutaneous chondroblastic osteosarcoma was suggested after excluding an origin in bone or other primary tumor sites by imaging techniques.
  • The patient underwent postoperative chemotherapy and is currently alive with pulmonary metastases 15 months after surgery.
  • In summary, we report a unique case of cutaneous osteosarcoma of the chondroblastic subtype, diagnosed on incisional skin biopsy despite the absence of osteoid or bone during tumor sampling.
  • As a rule, when an obviously malignant 'chondrosarcoma' is identified, one should always consider this entity.
  • [MeSH-major] Osteosarcoma / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Chemotherapy, Adjuvant. Humans. Lung Neoplasms / secondary. Male. Middle Aged. Thigh / pathology

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18190451.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


31. Fang Z, Matsumoto S, Ae K, Kawaguchi N, Yoshikawa H, Ueda T, Ishii T, Araki N, Kito M: Postradiation soft tissue sarcoma: a multiinstitutional analysis of 14 cases in Japan. J Orthop Sci; 2004;9(3):242-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postradiation soft tissue sarcoma: a multiinstitutional analysis of 14 cases in Japan.
  • Radiation therapy (RT) is commonly used to treat malignant tumors, but it leads to side effects and complications.
  • This article focuses on the clinical manifestations, pathological characteristics, and therapeutic effects concerning postradiation soft tissue sarcomas (PRSTSs).
  • Their histological types were malignant fibrous histiocytoma (eight cases), extraskeletal osteosarcoma (four cases), fibrosarcoma (one case), and leiomyosarcoma (one case).
  • The primary diagnoses, RT history, latent period, and outcome of treatment were studied retrospectively.
  • The original tumors included uterine cancer (seven cases), breast cancer (four cases), synovial sarcoma (one case), squamous cell carcinoma (one case), and Hodgkin's disease (one case).
  • There were 13 women and 1 man, with ages ranging from 23 to 77 years (mean 58 years) at the time of the appearance of the PRSTS.
  • RT doses ranged from 48 to 91 Gy (mean 62 Gy).
  • Altogether, 4 of 13 patients (31%) had recurrence of the sarcoma after resection.
  • One of three who underwent RT and one of five who underwent chemotherapy (CT) responded.
  • Because adjuvant therapies including RT and CT had a poor effect on PRSTSs, the primary treatment of PRSTSs should be radical resection with a wide margin.
  • [MeSH-major] Neoplasms, Second Primary / surgery. Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Breast Neoplasms / radiotherapy. Female. Histiocytoma, Benign Fibrous / etiology. Histiocytoma, Benign Fibrous / surgery. Humans. Japan. Male. Middle Aged. Neoplasm Recurrence, Local. Radiotherapy / adverse effects. Radiotherapy Dosage. Uterine Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] The Japanese Orthopaedic Association
  • (PMID = 15168177.001).
  • [ISSN] 0949-2658
  • [Journal-full-title] Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association
  • [ISO-abbreviation] J Orthop Sci
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Japan
  •  go-up   go-down


32. Paulides M, Kremers A, Stöhr W, Bielack S, Jürgens H, Treuner J, Beck JD, Langer T, German Late Effects Working Group in the Society of Pediatric Oncology and Haematology (GPOH): Prospective longitudinal evaluation of doxorubicin-induced cardiomyopathy in sarcoma patients: a report of the late effects surveillance system (LESS). Pediatr Blood Cancer; 2006 Apr;46(4):489-95
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective longitudinal evaluation of doxorubicin-induced cardiomyopathy in sarcoma patients: a report of the late effects surveillance system (LESS).
  • We herein report the results of observations on the frequency of cardiomyopathy in doxorubicin-treated sarcoma patients in Germany, Austria, and Switzerland.
  • PROCEDURE: The Late Effects Surveillance System (LESS) prospectively collects longitudinal data on late sequelae of antineoplastic therapy in Ewing-, soft tissue-, and osteosarcoma patients treated within the therapy trial protocols of the German Society of Pediatric Oncology and Hematology.
  • Two hundred sixty-five relapse-free patients who had received doxorubicin for the treatment within the EICESS-92/EURO-E.W.I.N.G.
  • -99, COSS-96, and CWS-96 therapy trials were serially examined by echocardiography.
  • Their mean age at the end of therapy was 13 +/- 5 years.
  • The mean follow-up time was 34 +/- 12 months.
  • Cardiomyopathy manifested in 11 cases already under antineoplastic therapy and in the remaining nine cases at a median of 26 days (range: 17-174 days) after stopping antineoplastic therapy.
  • Univariate and multivariable analysis did not confirm any of the known risk factors for developing anthracycline-induced cardiomyopathy in our patient group within the described time interval.
  • CONCLUSIONS: After a mean follow-up of 34 +/- 12 months, cumulative incidence of doxorubicin-induced cardiomyopathy in our pediatric sarcoma patients was at the lower end of that reported by other groups.
  • [MeSH-major] Cardiomyopathies / chemically induced. Doxorubicin / adverse effects. Product Surveillance, Postmarketing. Sarcoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Austria / epidemiology. Child. Child, Preschool. Cohort Studies. Comorbidity. Female. Follow-Up Studies. Germany / epidemiology. Humans. Infant. Longitudinal Studies. Male. Prospective Studies. Switzerland / epidemiology. Time






Advertisement